Citigroup’s Alexza Pharmaceuticals Inc ALXA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q2
Sell
-602
Closed 7787
2016
Q1
$0 Sell
602
-8
-1% -$4 ﹤0.01% 8074
2015
Q4
$0 Buy
+610
New +$629 ﹤0.01% 8153
2015
Q3
Sell
-5,412
Closed -$6K 8110
2015
Q2
$6K Buy
+5,412
New +$8.12K ﹤0.01% 6711
2015
Q1
Sell
-957
Closed -$1K 7648
2014
Q4
$1K Buy
957
+757
+379% +$1.35K ﹤0.01% 7047
2014
Q3
$0 Hold
200
﹤0.01% 7492
2014
Q2
$1K Sell
200
-1,620
-89% -$7K ﹤0.01% 7043
2014
Q1
$8K Buy
1,820
+1,620
+810% +$8.31K ﹤0.01% 6457
2013
Q4
$1K Hold
200
﹤0.01% 6921
2013
Q3
$1K Sell
200
-1,000
-83% -$4.71K ﹤0.01% 6737
2013
Q2
$5K Buy
+1,200
New +$5.44K ﹤0.01% 6346

Citigroup's ALXA Position: Q2 2016 in Review

Citigroup sold out of Alexza Pharmaceuticals Inc (ALXA) in Q2 2016, closing a stake of 602 shares.

Citigroup first reported a position in ALXA in Q2 2013 and held it in 10 quarters. The position peaked at $8K in Q1 2014. 0 funds tracked by Wall St. Rank hold ALXA as of Q2 2016.

  • Citigroup reported no remaining Alexza Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • Citigroup sold 602 Alexza Pharmaceuticals Inc shares in Q2 2016.
  • Citigroup first reported a position in Alexza Pharmaceuticals Inc in Q2 2013 and held it in 10 quarters.
  • Citigroup's Alexza Pharmaceuticals Inc position peaked at $8K in Q1 2014.
  • 0 funds tracked by Wall St. Rank held Alexza Pharmaceuticals Inc as of Q2 2016.

Based on Citigroup's 13F filing for Q2 2016, filed 12 Aug 2016.